For the Culture By The Culture. ISSN: 3064-9331.
A new Supreme Court ruling just cracked the door for civil RICO lawsuits in legal cannabis. If you think this won’t hit your dispensary, think again. Here’s what every grower, brand, and budtender needs to know.
Weed is getting cheaper but it’s not a win. Behind those $49 ounces and $2 prerolls is an industry bleeding out. Overproduction, bad policy, and corporate greed are killing quality, crushing independents, and leaving consumers with less than they bargained for. This isn’t a correction. It’s collapse.
The DEA is dragging its feet on cannabis rescheduling despite over 43,000 public comments and a formal Schedule III recommendation from HHS. What’s the hold-up? This deep-dive exposes the legal limbo, political stall tactics, and why America’s weed policy is still frozen in time.
Increasing tariffs and trade policies are driving up prices for cannabis accessories, impacting consumers who face strategic price hikes disguised as inflation. Major corporations pass these costs to customers while small producers struggle. The industry’s silence on these issues highlights economic manipulation, urging consumers to support local brands and demand transparency.
In a bizarre twist of bureaucratic brilliance, the DEA has reclassified marijuana as a leafy green vegetable—officially adding it to the American food pyramid. From salad bowls to school lunches, the War on Drugs just got edible. Satirical? Yes. Unbelievable? Barely.
The DEA is delaying the rescheduling of marijuana from Schedule I, despite overwhelming scientific support and recommendations from health authorities. This stalling harms the cannabis industry, patients, and communities affected by marijuana criminalization. Political influences from big pharmaceutical companies contribute to this resistance, prolonging the adverse effects of current drug policies.
